Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR4 | P22455 | 13/20 | 0.54 |
| ▸ | FGFR1 | P11362 | 12/20 | 0.54 |
| ▸ | RET | P07949 | 1/20 | 0.51 |
| ▸ | KIF5B | P33176 | 1/20 | 0.51 |
| ▸ | BTK | Q06187 | 2/20 | 0.49 |
| ▸ | FGFR2 | P21802 | 4/20 | 0.49 |
| ▸ | EGFR | P00533 | 3/20 | 0.49 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.47 |
| ▸ | KDR | P35968 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17065561 | 0.91 | BTK (0.58) | FGFR4FGFR1RETKIF5BBTK | |
| SCHEMBL17065742 | 0.91 | EGFR (0.51) | FGFR4FGFR1RETKIF5BBTK | |
| SCHEMBL17065555 | 0.88 | FGFR4 (0.51) | FGFR4FGFR1RETKIF5BBTK | |
| SCHEMBL17065654 | 0.87 | FGFR4 (0.53) | FGFR4FGFR1RETKIF5BFGFR2 | |
| SCHEMBL17065604 | 0.86 | BTK (0.59) | FGFR4FGFR1RETKIF5BBTK | |
| SCHEMBL18335272 | 0.86 | BTK (0.62) | FGFR4FGFR1BTKFGFR2EGFR | |
| SCHEMBL18335308 | 0.86 | FGFR4 (0.49) | FGFR4FGFR1RETKIF5BBTK | |
| SCHEMBL17065594 | 0.84 | FGFR4 (0.51) | FGFR4FGFR1RETKIF5BBTK | |
| SCHEMBL17065726 | 0.83 | BTK (0.61) | FGFR4FGFR1BTKFGFR2EGFR | |
| SCHEMBL18335350 | 0.82 | BTK (0.62) | FGFR4FGFR1RETKIF5BBTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160376277-A1 | NOVEL HETEROCYCLIC COMPOUNDS | CADILA HEALTHCARE LIMITED (IN) | 2016-12-29 | — | — | US | claimed |
| EP-3102579-A2 | HETEROCYCLIC COMPOUNDS | Cadila Healthcare Limited (IN) | 2016-12-14 | — | — | EP | claimed |
| WO-2015132799-A2 | NOVEL HETEROCYCLIC COMPOUNDS | CADILA HEALTHCARE LIMITED (IN) | 2015-09-11 | — | — | WO | claimed |
| EP-3102579-B1 | HETEROCYCLIC COMPOUNDS | CADILA HEALTHCARE LTD (IN) | 2019-04-10 | — | — | EP | disclosed |
| US-9840509-B2 | Heterocyclic compounds | CADILA HEALTHCARE LIMITED (IN) | 2017-12-12 | — | — | US | disclosed |
| US-9840509-B2 | Heterocyclic compounds | CADILA HEALTHCARE LIMITED (IN) | 2017-12-12 | — | — | US | disclosed |
| US-9840509-B2 | Heterocyclic compounds | CADILA HEALTHCARE LIMITED (IN) | 2017-12-12 | — | — | US | disclosed |
| US-20160376277-A1 | NOVEL HETEROCYCLIC COMPOUNDS | CADILA HEALTHCARE LIMITED (IN) | 2016-12-29 | — | — | US | disclosed |
| US-20160376277-A1 | NOVEL HETEROCYCLIC COMPOUNDS | CADILA HEALTHCARE LIMITED (IN) | 2016-12-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160376277-A1 | NOVEL HETEROCYCLIC COMPOUNDS | BTK, LYN, SYK | FGFR4 725/4885FGFR1 419/4885RET 504/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.